A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.

ABSTRACT:

Background and purpose

Alvespimycin, a new generation of heat shock protein 90 (Hsp90) inhibitor in clinical trial, is a promising therapeutic agent for cancer. Pharmacokinetic models of alvespimycin would help in the understanding of drug disposition, predicting drug exposure and interpreting dose-response relationship. In the present study we aimed to develop a physiologically based pharmacokinetic (PBPK) model of alvespimycin in mice and evaluate the utility of the model for predicting alvespimycin disposition in other species.

Experimental approach

A literature search was performed to collect pharmacokinetic data for alvespimycin. A PBPK model was initially constructed to demonstrate the disposition of alvespimycin in mice, and then extrapolated to rats and humans by tak

SUBMITTER: Hu ZY 

PROVIDER: S-EPMC4243854 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature